Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes

scientific article published on 4 May 2009

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1161/CIRCULATIONAHA.109.851949
P698PubMed publication ID19414633
P5875ResearchGate publication ID24400963

P50authorEugene BraunwaldQ322114
Elliott M AntmanQ64496972
John BrandtQ87611018
Marc S SabatineQ89851175
Jessica L. MegaQ114341315
Stephen D WiviottQ114427160
Sandra L CloseQ114444050
Richard D HockettQ114444051
William L MaciasQ114444052
P2093author name stringLei Shen
Joseph R Walker
P433issue19
P407language of work or nameEnglishQ1860
P921main subjectpharmacokineticsQ323936
pharmacodynamicsQ725307
P304page(s)2553-2560
P577publication date2009-05-04
P1433published inCirculationQ578091
P1476titleCytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes
P478volume119

Reverse relations

cites work (P2860)
Q379654812011 ACCF/AHA focused update of the guidelines for the management of patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (updating the 2007 Guideline): highlights for the clinician.
Q57774051A Risk–Benefit Assessment of Prasugrel, Clopidogrel, and Genotype-Guided Therapy in Patients Undergoing Percutaneous Coronary Intervention
Q64882378A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease.
Q34150640A case of resistance to clopidogrel and prasugrel after percutaneous coronary angioplasty.
Q37788682A comparison of the metabolism of clopidogrel and prasugrel
Q37973114A comprehensive comparative review of adenosine diphosphate receptor antagonists
Q54183735A randomized controlled trial of adjunctive Bunchang Naoxintong Capsule (步长脑心通胶囊) versus maintenance dose clopidogrel in patients with CYP2C19*2 polymorphism.
Q37908891A systematic review on pharmacogenetics in cardiovascular disease: is it ready for clinical application?
Q89064053A trial of type 12 purinergic (P2Y12) receptor inhibition with prasugrel identifies a potentially distinct endotype of patients with aspirin-exacerbated respiratory disease
Q57764209ANMCO/SICI-GISE paper on antiplatelet therapy in acute coronary syndrome
Q37998114Acute coronary syndromes: considerations for improved acceptance and implementation of management guidelines
Q36807413Advances in antiplatelet technologies to improve cardiovascular disease morbidity and mortality: a review of ticagrelor
Q38958862Advocating cardiovascular precision medicine with P2Y12 receptor inhibitors
Q34577974An algorithm for use of prasugrel (effient) in patients undergoing cardiac catheterization and percutaneous coronary intervention.
Q47231767Analysis of CYP2C19 Genetic Polymorphism in a Large Ethnic Hakka Population in Southern China
Q38106501Antiplatelet and anticoagulant strategies in acute coronary syndrome: where we are in 2013.
Q26824701Antiplatelet and anticoagulation therapy for acute coronary syndromes
Q33948811Antiplatelet drug interactions with proton pump inhibitors
Q37882712Antiplatelet drug therapy: role of pharmacodynamic and genetic testing
Q37738868Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors
Q37684794Antiplatelet therapies for the treatment of cardiovascular disease
Q37798110Antiplatelet therapy in acute coronary syndromes
Q36160606Antiplatelet therapy in acute coronary syndromes: current agents and impact on patient outcomes
Q35660184Antithrombotic therapy in patients with acute coronary syndromes: a balance between protection from ischemic events and risk of bleeding.
Q42907062Antithrombotics in acute coronary syndromes: updates from the past year.
Q38132923Assessing post-treatment platelet reactivity: a focus on patient selection and setting.
Q37683552Balancing the benefits and risks of antiplatelet agents in patients with non-ST-segment elevated acute coronary syndromes and undergoing percutaneous coronary intervention
Q92263864Between a rock and a hard place: a high-risk patient with resistance to multiple P2Y12 antagonists
Q37831317Beyond efficacy: pharmacokinetic differences between clopidogrel, prasugrel and ticagrelor.
Q38073672CYP-mediated pharmacologic interference with optimal platelet inhibition
Q90217107CYP2C19*17 May Increase the Risk of Death Among Patients with an Acute Coronary Syndrome and Non-Valvular Atrial Fibrillation Who Receive Clopidogrel and Rivaroxaban
Q89585264CYP3A4*22 Impairs the Elimination of Ticagrelor, But Has No Significant Effect on the Bioactivation of Clopidogrel or Prasugrel
Q36696635Cardiovascular Pharmacogenomics--Implications for Patients With CKD.
Q38220502Cardiovascular drugs and the genetic response.
Q35447163Cardiovascular pharmacogenomics
Q38169969Cardiovascular pharmacogenomics: expectations and practical benefits
Q38106616Challenges and limitations in the interpretation of systematic reviews: making sense of clopidogrel and CYP2C19 pharmacogenetics.
Q86202099Circulating reticulated platelets over time in patients with myocardial infarction treated with prasugrel or ticagrelor
Q88258320Clinical Outcomes and Sustainability of Using CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Q37107608Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.
Q35603072Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy
Q98612878Clinical Utility of CYP2C19 Genotype-Guided Antiplatelet Therapy in Patients at Risk of Adverse Cardiovascular and Cerebrovascular Events: A Review of Emerging Evidence
Q26849254Clinical application of cardiovascular pharmacogenetics
Q37970334Clinical considerations of heritable factors in common heart failure
Q35033722Clinical evidence of interaction between clopidogrel and proton pump inhibitors
Q38059616Clinical impact of genetically determined platelet reactivity
Q52593402Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention.
Q38177048Clinical implications of drug-drug interactions with P2Y12 receptor inhibitors
Q34390050Clinical importance of aspirin and clopidogrel resistance
Q33825186Clinical pharmacogenetics implementation: approaches, successes, and challenges
Q51530037Clinical predictors of high posttreatment platelet reactivity to clopidogrel in Koreans.
Q93175682Clopidogrel Pharmacogenetics
Q50867606Clopidogrel Resistance in Neurovascular Stenting: Correlations between Light Transmission Aggregometry, VerifyNow, and the Multiplate.
Q42961054Clopidogrel and proton pump inhibitors: between a rock and a hard place
Q38830015Clopidogrel pharmacogenetics: from evidence to implementation
Q37627874Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations
Q38128171Clopidogrel, prasugrel, or ticagrelor? a practical guide to use of antiplatelet agents in patients with acute coronary syndromes
Q41141258Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease
Q30573045Clopidogrel: the data, the experience, and the controversies
Q38008466Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications
Q37629641Comparison of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Q91738100Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: a phase 3, randomised, non-inferiority trial (PRASTRO-I)
Q37774825Considerations in patients receiving oral antiplatelet therapy after acute coronary syndrome and percutaneous coronary intervention
Q91063306Cost-effectiveness analysis of pharmacogenomics-guided clopidogrel treatment in Spanish patients undergoing percutaneous coronary intervention
Q89637477Cost-effectiveness of CYP2C19-guided antiplatelet therapy in patients with acute coronary syndrome and percutaneous coronary intervention informed by real-world data
Q37445540Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel
Q45815157Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia
Q34166239Cost-utility analysis of genotype-guided antiplatelet therapy in patients with moderate-to-high risk acute coronary syndrome and planned percutaneous coronary intervention
Q35660767Critical appraisal of ticagrelor in the management of acute coronary syndrome
Q38362982Current antiplatelet agents: place in therapy and role of genetic testing
Q34382431Current concepts on antiplatelet therapy: focus on the novel thienopyridine and non-thienopyridine agents
Q58694656Dental management of patients on anti-thrombotic agents
Q41848961Determinants to optimize response to clopidogrel in acute coronary syndrome
Q39142325Development of a broad-based ADME panel for use in pharmacogenomic studies
Q53200993Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation: Which Regimen and for How Long?
Q34622955Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
Q42632671Effect of age on the pharmacokinetics and pharmacodynamics of prasugrel during multiple dosing: an open-label, single-sequence, clinical trial
Q35846138Effect of grapefruit juice on the bioactivation of prasugrel
Q37807398Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel
Q38023512Effects of VerifyNow P2Y12 test and CYP2C19*2 testing on clinical outcomes of patients with cardiovascular disease: a systematic review and meta-analysis
Q34352152Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease
Q60310000Effects of switching ticagrelor to clopidogrel on cardiovascular outcomes in patients with acute coronary syndrome
Q37685847Efficacy and safety of ticagrelor: a reversible P2Y12 receptor antagonist
Q37979178Emerging antiplatelet agents, differential pharmacology, and clinical utility
Q37670190Emerging drugs for acute myocardial infarction
Q37949587Emerging therapies for acute coronary syndromes
Q51749154Evaluation of the INNOVANCE PFA P2Y assay and its association with CYP2C19 genotypes.
Q38098452Expanding role of pharmacogenomics in the management of cardiovascular disorders
Q37497555Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention.
Q57794673Frequencies of poor metabolizer alleles of 12 pharmacogenomic actionable genes in Punjabi Sikhs of Indian Origin
Q91969049Frequency and clinical outcomes of CYP2C19 genotype-guided escalation and de-escalation of antiplatelet therapy in a real-world clinical setting
Q30359686Future translational applications from the contemporary genomics era: a scientific statement from the American Heart Association
Q43158045Genetic CYP2C19 polymorphism dependent non-responders to clopidogrel therapy--does structural design, dosing and induction strategies have a role to play?
Q88842612Genetic Determinants of P2Y12 Inhibitors and Clinical Implications
Q37991382Genetic and non-genetic factors affecting the response to clopidogrel therapy.
Q37697779Genetic causes of clopidogrel nonresponsiveness: which ones really count?
Q37989811Genetic determinants of response to cardiovascular drugs
Q34633385Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy
Q33988457Genetic regulation of platelet receptor expression and function: application in clinical practice and drug development
Q44258281Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis
Q34564576Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis
Q38131848Genetics of platelet inhibitor treatment
Q34109838Genomics in coronary artery disease: past, present and future
Q37907918Genotypic and phenotypic assessment of platelet function and response to P2Y12 antagonists
Q41432957Genotyping of CYP2C19 polymorphisms and its clinical validation in the ethnic Arab population
Q33863833Guided antithrombotic therapy: current status and future research direction: report on a National Heart, Lung and Blood Institute working group
Q38104273High prevalence of CYP2C19*2 allele in Roma samples: study on Roma and Hungarian population samples with review of the literature
Q35109254Humanizing thrombi in mice
Q46319910Identification of PEAR1 SNPs and their influences on the variation in prasugrel pharmacodynamics
Q37203987Impact of Cytochrome P450 2C19*2 and *3 on Clopidogrel Loading Dose in Saudi Patients with Acute Coronary Syndrome
Q42757370Impact of genetic polymorphisms in the clinical response of oral inhibitors of the platelet P2Y12 adenosine diphosphate (ADP) receptor
Q36441477Impact of genetic polymorphisms on clinical response to antithrombotics
Q64948132Impact of genetic polymorphisms on platelet function and response to anti platelet drugs.
Q26745754Impact of selective platelet inhibition in reducing cardiovascular risk - role of vorapaxar
Q99210892Impact of the CYP2C19*17 allele on outcomes in patients receiving genotype-guided antiplatelet therapy after percutaneous coronary intervention
Q50940254Implementation and evaluation of a CYP2C19 genotype-guided antiplatelet therapy algorithm in high-risk coronary artery disease patients.
Q54374494Implementation of inpatient models of pharmacogenetics programs.
Q33990428Implementing genotype-guided antithrombotic therapy
Q34981428Indirect estimation of the comparative treatment effect in pharmacogenomic subgroups
Q44986245Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease
Q38071262Influence of platelet reactivity on clinical outcome of patients with stable coronary artery disease.
Q34174915Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes
Q33561577Integrated analysis of pharmacokinetic data across multiple clinical pharmacology studies of prasugrel, a new thienopyridine antiplatelet agent
Q38012079Latest evidence in personalized antiplatelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention
Q37679719Limitations of current therapies to prevent thrombosis: a need for novel strategies
Q38476938Management of Coronary Artery Disease in South Asian Populations: Why and How to Prevent and Treat Differently
Q47658855Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention
Q48345994Multisite Investigation of Strategies for the Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy.
Q37768334New antithrombotic agents--insights from clinical trials
Q38257119Novel antiplatelet agents in acute coronary syndrome
Q33902628Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor
Q37880741Optimizing antiplatelet therapy in acute coronary syndrome and percutaneous coronary intervention
Q35141772Oral antiplatelet therapy in diabetes mellitus and the role of prasugrel: an overview
Q37762149Overcoming 'resistance' to antiplatelet therapy: targeting the issue of nonadherence
Q33853179Pantoprazole Does Not Reduce the Antiplatelet Effect of Clopidogrel: A Randomized Controlled Trial in Korea
Q58804403Percutaneous pleural drainage in patients taking clopidogrel: real danger or phantom fear?
Q26822796Personalized antiplatelet and anticoagulation therapy: applications and significance of pharmacogenomics
Q37877165Personalized antiplatelet therapy: review of the latest clinical evidence
Q41960992Personalized healthcare in clotting disorders
Q38682772Personalizing antiplatelet prescribing using genetics for patients undergoing percutaneous coronary intervention
Q38040698Personalizing antiplatelet therapy with clopidogrel.
Q37590925Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials
Q38018679Pharmacodynamic properties of antiplatelet agents: current knowledge and future perspectives
Q44877659Pharmacogenetic Analysis of the Model-Based Pharmacokinetics of Five Anti-HIV Drugs: How Does This Influence the Effect of Aging?
Q34161006Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions.
Q37924323Pharmacogenetics and pharmacogenomics of thienopyridines: clinically relevant?
Q37583599Pharmacogenetics and safety parameters for platelet P2Y12 receptor antagonists
Q37808224Pharmacogenetics guided anticoagulation
Q38148597Pharmacogenetics of antiplatelets and anticoagulants: a report on clopidogrel, warfarin and dabigatran.
Q23919667Pharmacogenetics, pharmacogenomics, and individualized medicine
Q64890735Pharmacogenomic considerations for antiplatelet agents: the era of precision medicine in stroke prevention and neurointerventional practice.
Q26997380Pharmacogenomics and cardiovascular disease
Q89890370Pharmacogenomics in Asian subpopulations and impacts on commonly prescribed medications
Q38117748Pharmacogenomics in cardiovascular disease: focus on aspirin and ADP receptor antagonists
Q37933413Pharmacogenomics in the assessment of therapeutic risks versus benefits: inside the United States Food and Drug Administration
Q38195628Pharmacogenomics of oral antiplatelet drugs.
Q34976915Pharmacogenomics: the genetics of variable drug responses
Q37927151Pharmacokinetic basis of the antiplatelet action of prasugrel
Q35640465Pharmacokinetics and pharmacodynamics following maintenance doses of prasugrel and clopidogrel in Chinese carriers of CYP2C19 variants
Q38154211Pharmacology of antiplatelet agents
Q38151563Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.
Q41052640Platelet Aggregation Inhibitory Effects and Pharmacokinetics of Prasugrel Used in Combination With Aspirin in Healthy Japanese Subjects
Q38007894Platelet function and inhibition in ischemic heart disease
Q38233284Platelet function inhibitors and platelet function testing in neurointerventional procedures.
Q38094681Platelet function testing and tailored antiplatelet therapy
Q38132252Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know
Q34264876Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial
Q33818356Potential Usefulness of Clopidogrel Pharmacogenetics in Cerebral Endovascular Procedures and Carotid Artery Stenting.
Q37818331Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development
Q38336838Prasugrel hydrochloride for the treatment of acute coronary syndromes.
Q38012439Prasugrel is effective and safe for neurointerventional procedures
Q43261109Prasugrel or clopidogrel in patients with coronary intervention
Q37905028Prasugrel resistance: fact or fiction
Q37982427Prasugrel versus clopidogrel antiplatelet therapy after acute coronary syndrome: matching treatments with patients
Q43430172Prasugrel versus high dose clopidogrel to overcome early high on clopidogrel platelet reactivity in patients with ST elevation myocardial infarction.
Q33584173Prasugrel vs. clopidogrel for cytochrome P450 2C19-genotyped subgroups: integration of the TRITON-TIMI 38 trial data
Q37579188Prasugrel: a review of its use in patients with acute coronary syndromes undergoing percutaneous coronary intervention
Q38007860Pre PCI hospital antithrombotic therapy for ST elevation myocardial infarction: striving for consensus
Q36210219Predicting inhaled corticosteroid response in asthma with two associated SNPs
Q44474790Prediction of prasugrel active metabolite concentrations from 2 downstream inactive metabolite concentrations using multilinear regression analysis
Q39622468Prophylactic Antiplatelet Medication in Endovascular Treatment of Intracranial Aneurysms: Low-Dose Prasugrel versus Clopidogrel
Q44999184Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling
Q64903262Rationale, Design, and Baseline Characteristics of the Prospective Japan Acute Myocardial Infarction Registry (JAMIR).
Q34131354Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice
Q38216600Recent advances in antithrombotic treatment for acute coronary syndromes.
Q37972231Recent advances in the pharmacogenetics of clopidogrel
Q37289886Reduced number of cardiovascular events and increased cost-effectiveness by genotype-guided antiplatelet therapy in patients undergoing percutaneous coronary interventions in the Netherlands
Q34624862Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis
Q37693951Relation of CYP2C19 loss-of-function polymorphism to the occurrence of stent thrombosis.
Q37799470Review article: combination of clopidogrel and proton pump inhibitors: implications for clinicians
Q38347110Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.
Q38401281Role of Genetic Testing in Patients undergoing Percutaneous Coronary Intervention
Q36441521Role of cytochrome P450 genotype in the steps toward personalized drug therapy
Q38048837Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors
Q34990721Routine screening for CYP2C19 polymorphisms for patients being treated with clopidogrel is not recommended
Q60018207Résistance au clopidogrel, tests génétiques et tests fonctionnels
Q44483899Safe and effective medicines for all: is personalized medicine the answer?
Q53704317Safety of Prasugrel loading in ruptured blister like aneurysm treated with a Pipeline device.
Q38209661Significance of antiplatelet therapy in emergency myocardial infarction treatment
Q41651465Significant Improvement of Antithrombotic Responses to Clopidogrel by Use of a Novel Conjugate as Revealed in an Arterial Model of Thrombosis
Q38970275Single or dual antiplatelet therapy after PCI.
Q37697014State of the art of new P2Y12 antagonists.
Q83117953Stent thrombosis: understanding and managing a critical problem
Q35015993Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.
Q37925009TRITON and beyond: new insights into the profile of prasugrel
Q40498149Tailored Thienopyridine therapy: no urgency for CYP2C19 genotyping
Q42204185The Affymetrix DMET Plus platform reveals unique distribution of ADME-related variants in ethnic Arabs
Q37462239The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
Q40157153The association between CYP2C19 genotype and of in-stent restenosis among patients with vertebral artery stent treatment
Q84968912The cost effectiveness of genetic testing for CYP2C19 variants to guide thienopyridine treatment in patients with acute coronary syndromes: a New Zealand evaluation
Q51816112The discovery and development of prasugrel.
Q38053481The evolution of antiplatelet therapy in the treatment of acute coronary syndromes: from aspirin to the present day.
Q38750444The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).
Q38603459The impact of switching P2Y12 receptor inhibitor therapy during index hospitalization: a systematic review
Q35683944The interaction between clopidogrel and proton pump inhibitors (PPI): is there any clinical relevance?
Q100504013The need of a multicomponent guiding approach to personalize clopidogrel treatment
Q26801867The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19
Q37913976The pharmacogenetics of antiplatelet agents: towards personalized therapy?
Q38003702The pharmacogenomics of sex hormone metabolism: breast cancer risk in menopausal hormone therapy
Q84443544The promises of personalized medicine
Q37576116Thienopyridine therapy and risk for cardiovascular events in secondary prevention
Q37914050Thienopyridine-associated drug-drug interactions: pharmacologic mechanisms and clinical relevance
Q41817424Towards personalized medicine based on platelet function testing for stent thrombosis patients
Q34608705Understanding the economic value of molecular diagnostic tests: case studies and lessons learned
Q37972109Unstable angina and non-ST elevation myocardial infarction
Q28553219Up-Regulation of CYP2C19 Expression by BuChang NaoXinTong via PXR Activation in HepG2 Cells
Q38161394Updates in antiplatelet agents used in cardiovascular diseases
Q30978916Use of genetic data to guide therapy in arterial disease
Q37936014Variability of clopidogrel response in patients with type 2 diabetes mellitus
Q43049704Voluntary exploratory data submissions to the US FDA and the EMA: experience and impact
Q38355060Vorapaxar in atherosclerotic disease management
Q37704842What is the risk of intensifying platelet inhibition beyond clopidogrel? A systematic review and a critical appraisal of the role of prasugrel
Q87450358[ENT surgery in patients with anticoagulants and platelet aggregation inhibitors]
Q83592968[Periinterventional antiplatelet therapy: from bench to bedside]
Q268299732012 ACCF/AHA focused update incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Associat

Search more.